May 2005
Worldwide Biotech;May2005, Vol. 17 Issue 5, p1
Trade Publication
Reports on a joint drug discovery program being pursued by the Global Alliance for TB Drug Development and GlaxoSmithKline to improve the treatment of tuberculosis (TB). Advantage of the program; Number of projects included in the joint research program; Goal of the TB Alliance.


Related Articles

  • GlaxoSmithKline Shortens R&D Cycle with JMP's Design of Experiments. Smith, Amy // Scientific Computing & Instrumentation;Oct2002, Vol. 19 Issue 11, p20 

    Explores the impact of statistical investigation of collected data on the drug development stage with reference to the experience of GlaxoSmithKline (GSK). Stages of drug development; Aim of GSK for shortened research and development cycle; Benefits of statistical investigation in drug development.

  • GSK'S Centres of Excellence for External Drug Discovery.  // Bio Outsourcing Asia;Mar2011, Vol. 3 Issue 4, p11 

    The article describes GlaxoSmithKline's (GSK) Centres of Excellence for External Drug Discovery (CEEDD). GSK's CEEDD is a pioneering team of about 25 people in GSK research and development tasked with forming multi-program, risk reward sharing alliances across all therapy areas. A CEEDD alliance...

  • Chroma Pact with GSK Carries $1B Potential.  // Bioworld Week;6/29/2009, Vol. 17 Issue 26, p4 

    The article offers information on the deal agreed between GlaxoSmithKline PLC (GSK) and Chroma Therapeutics Ltd. in Oxford, England. It is reported that Chroma got the contract worth $1 billion from GSK for the development of autoimmune and other inflammatory diseases treatments. Moreover,...

  • GSK-Funded Tempero Striking a Balance in Immune Response.  // Bioworld Week;5/2/2011, Vol. 19 Issue 18, p2 

    The article focuses on the Tempero Pharmaceuticals Inc. formed by GlaxoSmithKline PLC in an effort to carry a business plan for the creation of a target drug discovery platform. It states that Tempero works for a T-cell lineage that will play a role in inflammation and tissue damage. It mentions...

  • GSK backs patent pool for neglected diseases.  // Nature;2/19/2009, Vol. 457 Issue 7232, p949 

    The article discusses the decision by the pharmaceutical company GlaxoSmithKline (GSK) to share its patented knowledge regarding the development of medicines for neglected tropical diseases (NTDs), such as malaria and tuberculosis (TB), with drug companies, governments and nongovernmental...

  • The structure of Mycobacteria 2C-methyl-D-erythritol-2, 4-cyclodiphosphate synthase, an essential enzyme, provides a platform for drug discovery. Buetow, Lori; Brown, Amanda C.; Parish, Tanya; Hunter, William N. // BMC Structural Biology;2007, Vol. 7, p68 

    Background: The prevalence of tuberculosis, the prolonged and expensive treatment that this disease requires and an increase in drug resistance indicate an urgent need for new treatments. The 1-deoxy-D-xylulose 5-phosphate pathway of isoprenoid precursor biosynthesis is an attractive...

  • Agenda At-a-Glance.  // Applied Clinical Trials;2010 Partnerships Supplement, p24 

    The article offers information on the agenda of the 19th Annual Partnerships in Clinical Trials on April 12-14, 2010 at Orlando World Center Marriott in Orlando, Florida. It presents several charts that depict the schedule of conference events. It highlights several topics including the future...

  • Investigational protease inhibitor 640385 combats HIV resistance.  // PharmaWatch: Biotechnology;September 2003, Vol. 2 Issue 9, p4 

    Announces the first clinical results for 640385, an investigational HIV protease inhibitor jointly discovered by GlaxoSmithKline PLC and Vertex Pharmaceuticals Inc. Efficacy of the compound in combating HIV virus; Need for the in vitro results shown by the drug to be explored in clinical trials;...

  • GSK, Emory Initiatives Address Translational Science Flaws. Powers, Marie // BioWorld Insight;6/17/2013, Vol. 21 Issue 25, p1 

    The article discusses the efforts of the research institutes for improving the efficiency of drug development. It mentions the Discovery Fast track competition, an initiative taken by the global health care company GlaxoSmithKline PLC, of providing funds and resources to research labs. It...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics